|
Synonyms: COMPOUND I [WO2022005494] | HPP-737 | HPP737 | HY-1999
Compound class:
Synthetic organic
Comment: Prifemilast (HPP737/HY-1999) is an orally bioavailable phosphodiesterase 4 (PDE4) inhibitor [1]. It is designed for reduced CNS permeability compared to roflumilast, to reduce the risk of adverse psychiatric disorder effects. Note that we show the structure with the stereochemistry as defined in the INN record, and in [1]. PubChem CID 155670934 shows the structure without the absolute stereo.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| Prifemilast is intended as a treatment for immune-mediated inflammatory diseases, including inflammatory bowel, skin and respiratory diseases. PDE4 inhibitors block the degradation of cyclic AMP (cAMP) in immune and other cells, and this activity reduces the production of pro-inflammatory cytokines as an anti-inflammatory mechanism. |